The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis.
Liddle, J., Beaufils, B., Binnie, M., Bouillot, A., Denis, A.A., Hann, M.M., Haslam, C.P., Holmes, D.S., Hutchinson, J.P., Kranz, M., McBride, A., Mirguet, O., Mole, D.J., Mowat, C.G., Pal, S., Rowland, P., Trottet, L., Uings, I.J., Walker, A.L., Webster, S.P.(2017) Bioorg Med Chem Lett 27: 2023-2028
- PubMed: 28336141 
- DOI: https://doi.org/10.1016/j.bmcl.2017.02.078
- Primary Citation of Related Structures:  
5N7T - PubMed Abstract: 
A series of potent, competitive and highly selective kynurenine monooxygenase inhibitors have been discovered via a substrate-based approach for the treatment of acute pancreatitis. The lead compound demonstrated good cellular potency and clear pharmacodynamic activity in vivo.
Organizational Affiliation: 
GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK. Electronic address: john.2.liddle@gsk.com.